Mark Kupersmith, MD
img_Mark Kupersmith
PROFESSOR | Neurology
PROFESSOR | Neurosurgery
PROFESSOR | Ophthalmology
Are you a patient?
Neurology, Neuro-Ophthalmology, Ophthalmology (Eye)
Research Topics
MRI, Neuroscience, Vision
New topic

I have serve as Chair of the planning committee for NORDIC and directed NORDIC (February 2009-present), fulfilling all of the obligations outlined in NORDIC policies and in the Idiopathic Intracranial Hypertension Treatment Trial, the LIIHTT and for proposed studies, HIS and SiihTT. I intend to continue in the same capacity now as Director of the Enrollment and Resource Centers, administratively integrating studies, sites, investigators, reading centers, Data Coordinating and Biostatistical Center, managing sites and committees and overseeing finance, and scientifically contributing to the multi-site studies conducted across the US and Canada by NORDIC (Neuro-Ophthalmology Research Disease Investigator Consortium).


I direct an ECRIP center award at NYEEI, title 'Noninvasive optical imaging detection of changes in the peripapillary retina and optic nerve head due to damage of the optic nerve' which is currently studying glaucoma, optic neuritis, NAION, giant cell arteritis, and NMO. Each project is headed by a 'fellow' who are all subspecialty trained ophthalmologists or neurologists.

MD, Northwestern University Feinberg School of Medicine

Residency, Neurology, NYU Medical Center

Residency, Ophthalmology, NYU Medical Center


American Board of Ophthalmology
American Board of Psychiatry and Neurology

New award

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Kupersmith during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Company Founder:

  • SafeTherapeutics, LLC

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • SafeTherapeutics, LLC

Royalty Payments:

  • SafeTherapeutics, LLC

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.